An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

"Gilead wins positive European approval opinion for twice-yearly HIV injection" was originally created and published by ...

Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

On Stocktwits, retail sentiment around Pheton is trending in the ‘extremely bullish’ territory, coupled with ‘extremely high’ ...

BMO Capital keeps an Outperform rating Gilead (GILD) after the Wall Street Journal reported that Robert F. Kennedy Jr. plans ...

With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead Sciences, Hookipa Pharma has ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Several of the events took place at ‘upscale restaurants’ in San Francisco, at costs of up to $163 per person, according to ...

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shares of Gilead Sciences Inc. GILD slid 2.15% to $112.29 Thursday, on what proved to be an all-around rough trading session ...